Terms: = Endocrine gland cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Prognosis
60 results:
1. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
Horvat NK; Karpovsky I; Phillips M; Wyatt MM; Hall MA; Herting CJ; Hammons J; Mahdi Z; Moffitt RA; Paulos CM; Lesinski GB
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38191243
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic impact of the distance from the root of splenic artery to tumor in the patients with pancreatic body or tail cancer.
Minagawa T; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Sasaki K; Uesaka K
Pancreatology; 2024 Feb; 24(1):100-108. PubMed ID: 38102055
[TBL] [Abstract] [Full Text] [Related]
3. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles.
Kumar V; Mahato RI
Cancer Lett; 2023 Nov; 579():216462. PubMed ID: 37924937
[TBL] [Abstract] [Full Text] [Related]
4. Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian cancer-Looking Back and Forward.
Okła K
Cells; 2023 Jul; 12(14):. PubMed ID: 37508575
[TBL] [Abstract] [Full Text] [Related]
5. Modified Appleby procedure for locally advanced pancreatic carcinoma: A primer for the radiologist.
Sindayigaya R; Barat M; Tzedakis S; Dautry R; Dohan A; Belle A; Coriat R; Soyer P; Fuks D; Marchese U
Diagn Interv Imaging; 2023 Oct; 104(10):455-464. PubMed ID: 37301694
[TBL] [Abstract] [Full Text] [Related]
6. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T; Makiyama A; Shimokawa M; Otsuka T; Shinohara Y; Koga F; Ueda Y; Nakazawa J; Otsu S; Komori A; Arima S; Fukahori M; Taguchi H; Honda T; Shibuki T; Nio K; Ide Y; Ureshino N; Mizuta T; Mitsugi K; Akashi K; Baba E
Sci Rep; 2023 May; 13(1):8815. PubMed ID: 37258608
[TBL] [Abstract] [Full Text] [Related]
7. car-T Cells in the Treatment of Ovarian cancer: A Promising Cell Therapy.
Zhang XW; Wu YS; Xu TM; Cui MH
Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979400
[TBL] [Abstract] [Full Text] [Related]
8. Construction of car-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
[TBL] [Abstract] [Full Text] [Related]
9. Progress and prospects for use of cellular immunotherapy in pancreatic cancer.
Tian J; Bai T; Zhang Z; Zhai X; Wang K; Gao X; Yan B
J Cancer Res Ther; 2022 Dec; 18(7):1867-1875. PubMed ID: 36647944
[TBL] [Abstract] [Full Text] [Related]
10. Association between the Preoperative
Funamizu N; Sogabe K; Shine M; Honjo M; Sakamoto A; Nishi Y; Matsui T; Uraoka M; Nagaoka T; Iwata M; Ito C; Tamura K; Sakamoto K; Ogawa K; Takada Y
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558435
[TBL] [Abstract] [Full Text] [Related]
11. Pretreatment Nutritional Status in Combination with Inflammation Affects Chemotherapy Interruption in Women with Ovarian, Fallopian Tube, and Peritoneal cancer.
Nomoto N; Tate S; Arai M; Iizaka S; Mori C; Sakurai K
Nutrients; 2022 Dec; 14(23):. PubMed ID: 36501212
[TBL] [Abstract] [Full Text] [Related]
12. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS; Pellat A; Brezault C; Dhooge M; Coriat R
ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
[TBL] [Abstract] [Full Text] [Related]
13. Pediatric adrenocortical carcinoma.
Ilanchezhian M; Varghese DG; Glod JW; Reilly KM; Widemann BC; Pommier Y; Kaplan RN; Del Rivero J
Front Endocrinol (Lausanne); 2022; 13():961650. PubMed ID: 36387865
[TBL] [Abstract] [Full Text] [Related]
14. Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy.
Gupta R; Jit BP; Kumar S; Mittan S; Tanwer P; Ray MD; Mathur S; Perumal V; Kumar L; Rath GK; Sharma A
Epigenomics; 2022 Jul; 14(14):865-886. PubMed ID: 35872653
[TBL] [Abstract] [Full Text] [Related]
15. Recent Advances in IL-13Rα2-Directed cancer Immunotherapy.
Knudson KM; Hwang S; McCann MS; Joshi BH; Husain SR; Puri RK
Front Immunol; 2022; 13():878365. PubMed ID: 35464460
[TBL] [Abstract] [Full Text] [Related]
16. Construction and Characterization of Cadherin 6 (CDH6)-Targeting Chimeric Antigen Receptor (car) Modified T Cells.
Pang L; Ren F; Xu X; Fu L; Wang T; Guo Z
J Environ Pathol Toxicol Oncol; 2022; 41(1):55-71. PubMed ID: 35378004
[TBL] [Abstract] [Full Text] [Related]
17. Longitudinal Analysis of Human Pancreatic Adenocarcinoma Development Reveals Transient Gene Expression Signatures.
Kim J; Ekstrom T; Yang W; Donahue G; Grygoryev D; Ngo TTM; Muschler JL; Morgan T; Zaret KS
Mol Cancer Res; 2021 Nov; 19(11):1854-1867. PubMed ID: 34330844
[TBL] [Abstract] [Full Text] [Related]
18. Distal pancreatectomy with En bloc celiac axis resection for locally advanced pancreatic body/tail cancer: A systematic review and meta-analysis.
Liu L; Liu TX; Huang WX; Yang Z; Wang S; Da MX; Dong Y
Asian J Surg; 2022 Jan; 45(1):51-61. PubMed ID: 34187724
[TBL] [Abstract] [Full Text] [Related]
19. Oncolytic adeno-immunotherapy modulates the immune system enabling car T-cells to cure pancreatic tumors.
Rosewell Shaw A; Porter CE; Yip T; Mah WC; McKenna MK; Dysthe M; Jung Y; Parihar R; Brenner MK; Suzuki M
Commun Biol; 2021 Mar; 4(1):368. PubMed ID: 33742099
[TBL] [Abstract] [Full Text] [Related]
20. Germline EGFR variants are over-represented in adolescents and young adults (AYA) with adrenocortical carcinoma.
Akhavanfard S; Yehia L; Padmanabhan R; Reynolds JP; Ni Y; Eng C
Hum Mol Genet; 2021 Jan; 29(22):3679-3690. PubMed ID: 33326033
[TBL] [Abstract] [Full Text] [Related]
[Next]
